Christian Maare
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christian Maare has a total of 203 co-authors. Here are the top co-authors by number of shared publications:
- Jørgen Johansen
Institute of Clinical Research, University of Southern Denmark, Denmark; Department of Oncology, Odense University Hospital, Denmark
14 shared publications - Jesper Grau Eriksen
Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark
11 shared publications - Jens Overgaard
Department of Experimental Clinical Oncology Aarhus University Hospital Aarhus Denmark
10 shared publications - Jeppe Friborg
Department of Oncology Copenhagen University Hospital Rigshospitalet Copenhagen Denmark
8 shared publications Maria Andersen
Department of Oncology Aalborg University Hospital Aalborg Denmark
8 shared publicationsTorben Skovsgaard
Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev Ringvej, DK-2730 Herlev, Denmark
8 shared publications
Latest Publications
- Open Access
- 16 September 2026
- Published by Wiley in Head & Neck
Pattern of Failure in Nasopharyngeal Carcinoma After Radiotherapy in a Low‐Incidence Population: A DAHANCA Study
Background: Nasopharyngeal carcinoma (NPC) is uncommon in many populations. Most existing clinical evidence comes from endemic areas, where Epstein–Barr virus (EBV)‐associated subtypes predominate. We analyzed patterns of failure in a population‐based cohort from Denmark, a low‐incidence setting. Methods: Patients with NPC treated with curative intent between 2000 and 2018 were identified through the Danish Head and Neck Cancer Study Group (DAHANCA) database and subsequently validated. Results: We identified 331 patients. The 5‐year cumulative incidence of failure was 31.1% for any failure, 16.9% for locoregional failure, and 14.2% for distant failure. Distant failure occurred almost exclusively in locally advanced disease (Stage I: 0%; II: 4.2%; III: 21.1%; and IVa: 19.4%). Rates of any failure were comparable between EBV‐positive (29.7%) and EBV‐negative (32.0%) tumors. Conclusions: In this low‐incidence population, the likelihood of failure after primary radiotherapy for NPC did not differ by EBV status. Distant failure was largely confined to patients with locally advanced stages.
- 16 September 2026
- Published by Wiley in Head & Neck
Open AccessPattern of Failure in Nasopharyngeal Carcinoma After Radiotherapy in a Low‐Incidence Population: A DAHANCA Study
Background: Nasopharyngeal carcinoma (NPC) is uncommon in many populations. Most existing clinical evidence comes from endemic areas, where Epstein–Barr virus (EBV)‐associated subtypes predominate. We analyzed patterns of failure in a population‐based cohort from Denmark, a low‐incidence setting. Methods: Patients with NPC treated with curative intent between 2000 and 2018 were identified through the Danish Head and Neck Cancer Study Group (DAHANCA) database and subsequently validated. Results: We identified 331 patients. The 5‐year cumulative incidence of failure was 31.1% for any failure, 16.9% for locoregional failure, and 14.2% for distant failure. Distant failure occurred almost exclusively in locally advanced disease (Stage I: 0%; II: 4.2%; III: 21.1%; and IVa: 19.4%). Rates of any failure were comparable between EBV‐positive (29.7%) and EBV‐negative (32.0%) tumors. Conclusions: In this low‐incidence population, the likelihood of failure after primary radiotherapy for NPC did not differ by EBV status. Distant failure was largely confined to patients with locally advanced stages.
- Open Access
- 18 August 2026
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 86 (6) , 694-701
The clinical impact of 131-iodine whole-body scintigraphy following 131-iodine therapy of thyroid cancer
The incidence of thyroid cancer has increased globally in recent years, primarily due to a more widespread use of imaging particularly in terms of ultrasonography and subsequent biopsies [1]. The a...
- 18 August 2026
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 86 (6) , 694-701
Open AccessThe clinical impact of 131-iodine whole-body scintigraphy following 131-iodine therapy of thyroid cancer
The incidence of thyroid cancer has increased globally in recent years, primarily due to a more widespread use of imaging particularly in terms of ultrasonography and subsequent biopsies [1]. The a...
- Open Access
- 19 June 2026
- Published by Elsevier in SSRN Electronic Journal
Spatial correlation and hypoxia-driven dose escalation of FDG PET and FAZA PET for head and neck cancer
Background and purpose:Hypoxia is a negative prognostic factor in head and neck squamous cell carcinoma (HNSCC). Although hypoxic volumes (HVs) may be targeted with dose-escalated radiotherapy (RT), hypoxia PET tracers such as FAZA are not widely used clinically. Moderate correlations between FDG PET and hypoxia PET tracers have been reported, but their spatial overlap remains unclear. This study investigated the spatial relationship between FDG-defined volumes and FAZA-defined HVs and evaluated its impact on dose escalation (DE) in HNSCC. Material and methods:Six HNSCC patients underwent FDG PET/CT for RT planning and further with FAZA PET/CT at the beginning, middle, and end of RT. Clinical FDG PET-positive volumes were delineated and additional FDG volumes were created as 30%, 40%, and 50% of the maximum SUV within the GTV (FDG SUV30/40/50). The HV within the GTV was defined as a FAZA signal ≥1.4x that of a reference tissue and rigidly transferred to the FDG PET/CT. DE plans to 78 Gy for the FAZA HV and FDG SUV40 volumes, respectively, were created and coverage metrics extracted. Results:FAZA HVs remained spatially stable while decreasing in size during RT. FDG-defined volumes were generally larger than the “true” FAZA HVs, yielding small false negative volumes (0.0-2.7cm3) but larger false positive volumes (1.2-21.4cm3). FAZA HVs were well-covered by FDG Clinical DE plans (V95% = [97-100%]).Conclusion:In this exploratory study for HNSCC patients, FDG-defined volumes adequately covered FAZA-defined HVs. FDG should be investigated further as practical surrogate for hypoxia-guided DE RT in HNSCC.
- 19 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessSpatial correlation and hypoxia-driven dose escalation of FDG PET and FAZA PET for head and neck cancer
Background and purpose:Hypoxia is a negative prognostic factor in head and neck squamous cell carcinoma (HNSCC). Although hypoxic volumes (HVs) may be targeted with dose-escalated radiotherapy (RT), hypoxia PET tracers such as FAZA are not widely used clinically. Moderate correlations between FDG PET and hypoxia PET tracers have been reported, but their spatial overlap remains unclear. This study investigated the spatial relationship between FDG-defined volumes and FAZA-defined HVs and evaluated its impact on dose escalation (DE) in HNSCC. Material and methods:Six HNSCC patients underwent FDG PET/CT for RT planning and further with FAZA PET/CT at the beginning, middle, and end of RT. Clinical FDG PET-positive volumes were delineated and additional FDG volumes were created as 30%, 40%, and 50% of the maximum SUV within the GTV (FDG SUV30/40/50). The HV within the GTV was defined as a FAZA signal ≥1.4x that of a reference tissue and rigidly transferred to the FDG PET/CT. DE plans to 78 Gy for the FAZA HV and FDG SUV40 volumes, respectively, were created and coverage metrics extracted. Results:FAZA HVs remained spatially stable while decreasing in size during RT. FDG-defined volumes were generally larger than the “true” FAZA HVs, yielding small false negative volumes (0.0-2.7cm3) but larger false positive volumes (1.2-21.4cm3). FAZA HVs were well-covered by FDG Clinical DE plans (V95% = [97-100%]).Conclusion:In this exploratory study for HNSCC patients, FDG-defined volumes adequately covered FAZA-defined HVs. FDG should be investigated further as practical surrogate for hypoxia-guided DE RT in HNSCC.
- Open Access
- 12 January 2026
- Published by Elsevier in Oral Oncology
- Vol. 173, 107849
Prognostic significance of p16 and immune cell infiltration in recurrent/metastatic head and neck squamous cell carcinoma treated with PD-1 inhibition: a national DAHANCA cohort study
- 12 January 2026
- Published by Elsevier in Oral Oncology
- Vol. 173, 107849
Open AccessPrognostic significance of p16 and immune cell infiltration in recurrent/metastatic head and neck squamous cell carcinoma treated with PD-1 inhibition: a national DAHANCA cohort study
- Open Access
- 27 September 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 213, 111162
Failure pattern and salvage in head and neck cancer of unknown primary: A national study by DAHANCA
- 27 September 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 213, 111162
Open AccessFailure pattern and salvage in head and neck cancer of unknown primary: A national study by DAHANCA
- Open Access
- 21 September 2025
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 64, 1269-1275
Pembrolizumab as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a multi-institutional DAHANCA cohort study
Background and purpose: Pembrolizumab is frequently used for recurrent or metastatic head and neck squamous cell carcinoma (rmHNSCC) as first-line treatment. This study evaluates real-world effectiveness in a Danish and United Kingdom (UK) cohort. Patient/material and methods: Patients with confirmed rmHNSCC treated with pembrolizumab (2020–2024) as first-line palliative treatment were included consecutively. Data were collected from patient files at four Danish head and neck cancer centres (discovery cohort) and the Leeds Teaching Hospitals NHS Trust (comparison cohort). Primary endpoints were overall survival (OS) and progression-free survival (PFS). Results: In the discovery cohort (n = 228), a median OS of 10 months (95% [confidence interval [CI]: 10–12) and median PFS of 4 months (95% CI: 4–6) were found. Primary endpoints did not differ significantly between the discovery and comparison cohort. Baseline World Health Organization performance status appeared to negatively impact endpoints (hazard ratio: 1.4 [95% CI: 1.0–2.0]). Interpretation: In this real-world multi-centre study, pembrolizumab demonstrated efficacy equivalent to the registration studies in two independent cohorts.
- 21 September 2025
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 64, 1269-1275
Open AccessPembrolizumab as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a multi-institutional DAHANCA cohort study
Background and purpose: Pembrolizumab is frequently used for recurrent or metastatic head and neck squamous cell carcinoma (rmHNSCC) as first-line treatment. This study evaluates real-world effectiveness in a Danish and United Kingdom (UK) cohort. Patient/material and methods: Patients with confirmed rmHNSCC treated with pembrolizumab (2020–2024) as first-line palliative treatment were included consecutively. Data were collected from patient files at four Danish head and neck cancer centres (discovery cohort) and the Leeds Teaching Hospitals NHS Trust (comparison cohort). Primary endpoints were overall survival (OS) and progression-free survival (PFS). Results: In the discovery cohort (n = 228), a median OS of 10 months (95% [confidence interval [CI]: 10–12) and median PFS of 4 months (95% CI: 4–6) were found. Primary endpoints did not differ significantly between the discovery and comparison cohort. Baseline World Health Organization performance status appeared to negatively impact endpoints (hazard ratio: 1.4 [95% CI: 1.0–2.0]). Interpretation: In this real-world multi-centre study, pembrolizumab demonstrated efficacy equivalent to the registration studies in two independent cohorts.
- Open Access
- 26 August 2025
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 64, 1129-1135
Mutational profile of oropharyngeal squamous cell carcinoma in relation to HPV, tobacco smoking and prognosis with validation in the DAHANCA 19 randomized trial
Background and purpose: This study investigated prognostic biomarkers in oropharyngeal squamous cell carcinoma (OPSCC), with a focus on tumors related to human papillomavirus (HPV) infection and potential molecular effects of tobacco smoking, as smokers with HPV+ OPSCC often have poorer outcomes. Patients/material and methods: We first analyzed 56 previously untreated OPSCC patients (exploration cohort), assessing HPV status, gene expression related to hypoxia, tumor subtype, and radiosensitivity, together with next-generation sequencing (NGS) of cancer-related genes. A custom NGS panel was subsequently designed and validated in 162 patients from the DAHANCA 19 randomized controlled trial (RCT), all treated with curative (chemo-)radiotherapy. Results:In the exploration cohort (40 HPV+, 79%), the most common molecular events in HPV+ tumors were PIK3CA and ATR mutations and chromosome 3q amplification. ATR and CREBBP mutations occurred more often in heavy smokers (>10 pack-years), but these associations were not confirmed in the DAHANCA 19 cohort. No specific smoking-related mutational signature or link to TP53 mutations was observed. In the DAHANCA 19 cohort, 17 locoregional failures (LRF) occurred among 128 HPV+ patients. No unifying molecular features were identified. However, mutations in NFE2L2 and CASP8, as well as amplifications of 3q genes (BCL6, SOX2), were associated with LRF. Interpretation: In HPV+ OPSCC, only few molecular alterations appear to act as drivers or prognostic biomarkers. Importantly, no molecular features of tobacco smoking exposure were identified, and the mechanism behind the worse prognosis in smokers remains unclear.
- 26 August 2025
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 64, 1129-1135
Open AccessMutational profile of oropharyngeal squamous cell carcinoma in relation to HPV, tobacco smoking and prognosis with validation in the DAHANCA 19 randomized trial
Background and purpose: This study investigated prognostic biomarkers in oropharyngeal squamous cell carcinoma (OPSCC), with a focus on tumors related to human papillomavirus (HPV) infection and potential molecular effects of tobacco smoking, as smokers with HPV+ OPSCC often have poorer outcomes. Patients/material and methods: We first analyzed 56 previously untreated OPSCC patients (exploration cohort), assessing HPV status, gene expression related to hypoxia, tumor subtype, and radiosensitivity, together with next-generation sequencing (NGS) of cancer-related genes. A custom NGS panel was subsequently designed and validated in 162 patients from the DAHANCA 19 randomized controlled trial (RCT), all treated with curative (chemo-)radiotherapy. Results:In the exploration cohort (40 HPV+, 79%), the most common molecular events in HPV+ tumors were PIK3CA and ATR mutations and chromosome 3q amplification. ATR and CREBBP mutations occurred more often in heavy smokers (>10 pack-years), but these associations were not confirmed in the DAHANCA 19 cohort. No specific smoking-related mutational signature or link to TP53 mutations was observed. In the DAHANCA 19 cohort, 17 locoregional failures (LRF) occurred among 128 HPV+ patients. No unifying molecular features were identified. However, mutations in NFE2L2 and CASP8, as well as amplifications of 3q genes (BCL6, SOX2), were associated with LRF. Interpretation: In HPV+ OPSCC, only few molecular alterations appear to act as drivers or prognostic biomarkers. Importantly, no molecular features of tobacco smoking exposure were identified, and the mechanism behind the worse prognosis in smokers remains unclear.
- Open Access
- 18 August 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 211, 111096
Radiotherapy quality assurance of patients with squamous cell carcinoma of the head and neck included in the DAHANCA 19 randomised phase III trial
- 18 August 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 211, 111096
Open AccessRadiotherapy quality assurance of patients with squamous cell carcinoma of the head and neck included in the DAHANCA 19 randomised phase III trial
- Open Access
- 14 August 2025
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 64, 1071-1078
Subsite variation of HPV-related p16-expression in oropharynx cancer: Incidence and prognostic impact in a population-based DAHANCA cohort 1986–2020
P16-expression are implemented in the TNM8 classification of oropharyngeal cancer (OPSCC). Based on a nationwide cohort, we provide a detailed description of subsite variation in the age-standardised incidence-rates of OPSCC alongside an evaluation of the prognostic impact of p16-expression according to subsite after primary radiotherapy (RT). Patient/material and methods: A total of 8,462 Danish OPSCC patients from 1986 to 2020 were identified in the DAHANCA-database, and tumours were grouped into ‘tonsil/base of tongue (BOT)’, ‘neighbouring subsites’ and ‘distant subsites’. Subsite-specific age-standardised incidence-rates were calculated, and outcome-analysis (loco-regional control, disease-free survival and overall-survival 5 years after the completion of RT) stratified by p16-status/subsite and restricted to curatively treated patients only (N = 3,387) was performed. Results: A 5-fold increase in the age-standardised incidence of OPSCC was observed and could be ascribed to the rise in p16-positive tumours of tonsil/BOT and neighbouring subsites only as neither the incidence rates nor the proportion of p16-positivity in distant subsites tumours changed over time. The prognostic impact of p16-status for all endpoints differed significantly across tumour subsites with the strongest association found in tonsil/BOT tumours, a diminishing but still significant impact in neighbouring subsite tumours and no significant impact in tumours arising in distant subsites. Interpretation: Our findings suggest that grouping all p16-positive OPSCC as one entity for staging and prognostication, as currently done in TNM8, is too simple as it does not accurately depict the differences in tumour biology and the consequent treatment response.
- 14 August 2025
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 64, 1071-1078
Open AccessSubsite variation of HPV-related p16-expression in oropharynx cancer: Incidence and prognostic impact in a population-based DAHANCA cohort 1986–2020
P16-expression are implemented in the TNM8 classification of oropharyngeal cancer (OPSCC). Based on a nationwide cohort, we provide a detailed description of subsite variation in the age-standardised incidence-rates of OPSCC alongside an evaluation of the prognostic impact of p16-expression according to subsite after primary radiotherapy (RT). Patient/material and methods: A total of 8,462 Danish OPSCC patients from 1986 to 2020 were identified in the DAHANCA-database, and tumours were grouped into ‘tonsil/base of tongue (BOT)’, ‘neighbouring subsites’ and ‘distant subsites’. Subsite-specific age-standardised incidence-rates were calculated, and outcome-analysis (loco-regional control, disease-free survival and overall-survival 5 years after the completion of RT) stratified by p16-status/subsite and restricted to curatively treated patients only (N = 3,387) was performed. Results: A 5-fold increase in the age-standardised incidence of OPSCC was observed and could be ascribed to the rise in p16-positive tumours of tonsil/BOT and neighbouring subsites only as neither the incidence rates nor the proportion of p16-positivity in distant subsites tumours changed over time. The prognostic impact of p16-status for all endpoints differed significantly across tumour subsites with the strongest association found in tonsil/BOT tumours, a diminishing but still significant impact in neighbouring subsite tumours and no significant impact in tumours arising in distant subsites. Interpretation: Our findings suggest that grouping all p16-positive OPSCC as one entity for staging and prognostication, as currently done in TNM8, is too simple as it does not accurately depict the differences in tumour biology and the consequent treatment response.
- Open Access
- 19 April 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 208, 110899
DAHANCA19: A randomized phase III study of primary curative (chemo)-radiotherapy and the EGFR-inhibitor zalutumumab for squamous cell carcinoma of the head and neck
- 19 April 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 208, 110899
Open AccessDAHANCA19: A randomized phase III study of primary curative (chemo)-radiotherapy and the EGFR-inhibitor zalutumumab for squamous cell carcinoma of the head and neck